On August 7th, 2018, the US District Court in Delaware ruled against Shire in its request for a preliminary injunction against Roche AG from creating, transporting, and marketing its recently approved drug Hemlibra in US, which received FDA approval to treat people with hemophilia A with inhibitors in 2017. This ruling means there are no legal limitations on the ability of physicians to prescribe Hemlibra at this time.
Read more about Roche/Genentech and Shire.
